Support for the efficacy of behavioural activation in treating anxiety in breast cancer patients

Hopko, Derek R.; Lejuez, Carl W.; Ryba, Marlena M.; Shorter, Rebecca L.; Bell, John L.

doi:10.1111/cp.12083

Cited by 20 publications

(18 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…toward the end of the study. These results show the efficiency of BA, as previously demonstrated in treatment for depression in cancer patients (Hopko et al, 2008; Hopko et al, 2015; Hopko et al, 2013; Hopko et al, 2016).…”

Section: Discussionsupporting

confidence: 86%

Effects of Behavioral Activation on the Quality of Life and Emotional State of Lung Cancer and Breast Cancer Patients During Chemotherapy Treatment

et al. 2017

View full text Add to dashboard Cite

Research suggests that the progressive abandonment of activities in cancer patients are related to depression and worse quality of life. Behavioral activation (BA) encourages subjects to activate their sources of reinforcement and modify the avoidance responses. This study assesses the effectiveness of BA in improving quality of life and preventing emotional disorders during chemotherapy treatment. One sample of lung cancer patients and another of breast cancer patients were randomized into a BA experimental group (E.G.. n = 50; E.G.. n = 33) and a control group (C.G.. n = 40; C.G. n = 35), respectively. In each session and in follow-ups (3/6/9 months), all participants completed different assessment scales. The results converge to show the effectiveness of BA, encouraging cancer patients to maintain rewarding activities which can activate their sources of day-to-day reinforcement and modify their experience avoidance patterns. BA appears to be a practical intervention which may improve social and role functioning and the emotional state of cancer patients during chemotherapy treatment.

show abstract

Section: Discussionsupporting

confidence: 86%

Effects of Behavioral Activation on the Quality of Life and Emotional State of Lung Cancer and Breast Cancer Patients During Chemotherapy Treatment

et al. 2017

View full text Add to dashboard Cite

show abstract

“…The results expand the evidence from previous studies of BA treatment in smokers with depressive symptoms in comorbidity with anxiety symptoms (Hopko et al, 2016;Leventhal, y Zvolensky, 2015;Reynolds et al, 2011;Soleimani et al, 2015). Even though BA was not developed for smoking treatment per se, it can be a critical addition to treatment planning for cigarette smokers with concomitant depressive and anxiety symptoms.…”

Section: Discussionsupporting

confidence: 86%

A preliminary study on the application of Behavioral Activation in the treatment of smoking in women

Sánchez-Angulo

Mairal

Padilla³

et al. 2021

PSYE

View full text Add to dashboard Cite

The present study evaluated the effectiveness of Behavioral Activation (BA) on women smokers with depression and anxiety symptoms who received multi-component treatment for smoking cessation. Forty-nine women were randomly assigned to two groups. 1) experimental: BA and varenicline and 2) control, cognitive behavioral therapy for smoking cessation and varenicline. Both treatments were applied in 10 twice-weekly. The Beck Depression Inventory II, the Beck Anxiety Inventory, the Fasgeström Test, Smokerlyzer® piCO monitor for carbon monoxide breath tests, and the Behavioral Activation Scale for Depression were used. Project-by-Project Analysis (PPA) was carried out with bivariate logistic regression, including only those who had completed the treatment and follow-ups. In the second, Intention-to-Treat Analysis (ITA) used the Kaplan-Meier non-parametric method and the Log Rank Test for all those initially randomized. The results showed that the abstinence rate with the BA treatment was higher than for the cognitive behavioral treatment for smoking cessation. Furthermore, BA loss was lower than with the standard treatment. We therefore conclude that BA + varenicline was effective from the end of the smoking cessation treatment to the six-month follow-up.

show abstract

“…Decreased social functioning has been identified as predictive of depression and anxiety symptoms in patients with cancer [31, 32]. Of interest, interventions aimed at improving social activity, such as behavioral activation therapy, which emphasizes systematically increasing the number of activities consistent with a person's values and goals, may be one effective way to target psychological distress [33]. In our sample, being married and having good functional status also may have mitigated during‐treatment depression and anxiety.…”

Section: Discussionmentioning

confidence: 99%

Serial Assessment of Depression and Anxiety by Patients and Providers in Women Receiving Chemotherapy for Early Breast Cancer

et al. 2020

View full text Add to dashboard Cite

Background Depression and anxiety are common in patients with breast cancer and associated with worse quality of life and treatment outcomes. Yet, these symptoms are often underrecognized and undermanaged in oncology practice. The objective of this study was to describe depression and anxiety severity and associated patient factors during adjuvant or neoadjuvant chemotherapy in women with early breast cancer using repeated single‐item reports. Materials and Methods Depression and anxiety were measured from consecutive patients and their clinicians during chemotherapy infusion visits. Associations between psychiatric symptoms and patient characteristics were assessed using Fisher's exact tests for categorical variables and t tests for continuous variables. The joint relationship of covariates significant in unadjusted analyses was evaluated using log‐binomial regression. Cohen's kappa was used to assess agreement between patient‐ and clinician‐reported symptoms. Results In a sample of 256 patients, 26% reported at least moderately severe depression, and 41% reported at least moderately severe anxiety during chemotherapy, representing a near doubling in the prevalence of these symptoms compared with before chemotherapy. Patient‐provider agreement was fair (depression: κ = 0.31; anxiety: κ = 0.28). More severe psychiatric symptoms were associated with being unmarried, having worse function, endorsing social activity limitations, using psychotropic medications, and having a mental health provider. In multivariable analysis, social activity limitations were associated with more severe depression (relative risk [RR], 2.17; 95% confidence interval [CI], 1.36–3.45) and anxiety (RR, 1.48; 95% CI, 1.05–2.09). Conclusion Oncologists frequently underestimate patients’ depression and anxiety and should consider incorporating patient‐reported outcomes to enhance monitoring of mental health symptoms. Implications for Practice In this sample of 256 patients with breast cancer, depression and anxiety, measured using single‐item toxicity reports completed by patients and providers, were very common during adjuvant or neoadjuvant chemotherapy. Patient‐reported depression and anxiety of at least moderate severity were associated with multiple objective indicators of psychiatric need. Unfortunately, providers underrecognized the severity of their patients’ mental health symptoms. The use of patient‐reported, single‐item toxicity reports can be incorporated into routine oncology practice and provide clinically meaningful information regarding patients’ psychological health.

show abstract

Support for the efficacy of behavioural activation in treating anxiety in breast cancer patients

Cited by 20 publications

References 53 publications

Effects of Behavioral Activation on the Quality of Life and Emotional State of Lung Cancer and Breast Cancer Patients During Chemotherapy Treatment

Effects of Behavioral Activation on the Quality of Life and Emotional State of Lung Cancer and Breast Cancer Patients During Chemotherapy Treatment

A preliminary study on the application of Behavioral Activation in the treatment of smoking in women

Serial Assessment of Depression and Anxiety by Patients and Providers in Women Receiving Chemotherapy for Early Breast Cancer

Contact Info

Product

Resources

About